Antibody–Drug Conjugates Emerge as Immune Modulators, Not Just Targeted Chemotherapy
A new review argues that antibody–drug conjugates act as immune modulators through immunogenic cell death, Fc-mediated effector functions and tumour ...
A new review argues that antibody–drug conjugates act as immune modulators through immunogenic cell death, Fc-mediated effector functions and tumour ...
A multicenter Central European real-world study finds sacituzumab govitecan delivers meaningful survival benefit and manageable toxicity in heavily pretreated metastatic ...
A new review in Annals of Hematology details how molecular profiling and a growing arsenal of targeted and immune-based therapies ...
The latest volume of SLAS Discovery showcases how artificial intelligence, deep learning and data-mining strategies are accelerating drug discovery across ...
A sweeping new review maps how the epithelial guardian protein MUC1, and especially its MUC1-C signaling subunit, is hijacked by ...
An international adaptive platform trial called Glo-BNHL will simultaneously test bispecific antibodies, antibody-drug conjugates and CAR T-cells in children and ...
Landmark trials from 2024 and 2025 are transforming breast cancer care by safely scaling back surgery while unleashing antibody-drug conjugates, ...
A new MD Anderson study finds that 57 percent of residual breast tumors lose HER2 overexpression after HER2-targeted neoadjuvant therapy, ...
A landmark review argues that tumour-agnostic immunotherapy succeeds only when biological rationale, validated biomarkers and health-system infrastructure are aligned, using ...
A single-cell atlas of 157,449 bladder cancer cells shows that antibody-drug conjugate targets rise and fall along a tumor differentiation ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine